Investing.com - Novartis ADR reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Novartis ADR announced earnings per share of $1.52 on revenue of $12.26B. Analysts polled by Investing.com anticipated EPS of $1.44 on revenue of $12.6B.
Novartis ADR shares are down 11.1% from the beginning of the year, still down 15.69% from its 52 week high of $99.84 set on February 12. They are under-performing the EUR/USD which is down 0% from the start of the year.
Novartis ADR follows other major Healthcare sector earnings this month
Novartis ADR's report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Abbott Labs had beat expectations on October 21 with third quarter EPS of $0.98 on revenue of $8.85B, compared to forecast for EPS of $0.91 on revenue of $8.54B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar